COVID-19
A week after Novavax submitted its Emergency Use Authorization materials to the FDA for its COVID-19 vaccine candidate. reports are coming out about the company’s problems with the production and delivery.
The COVID-19 pandemic has seen a full-blown effort from biopharma and researchers to develop new drugs and test old ones against the disease, with highly mixed results.
Antiviral pills against COVID-19 show promise for treating the disease, but they are not broadly accessible yet.
The same advantage against HIV-1 possessed by a person with the inactive CCR5 variant potentially doubles as resistance to any virus that capitalizes on or manipulates that receptor.
Business with customers in the pharma and biotech sector was a key revenue driver, said Thermo Fisher CEO Marc Casper, adding that this business grew by 25% over the year.
COVID-19 is a respiratory illness and presents many other symptoms, including blood clots. For more details and other COVID-19 news, continue reading.
COVID-19 causes certain conditions or is being implicated in their earlier onset. Type 1 diabetes and Parkinson’s disease are prime examples. According to researchers, it also may cause fetal inflammation.
For 2021, with $6.19 billion in sales the monoclonal antibody counted for a little less than one-third of Regeneron’s overall $16.07 billion revenue.
FDA Action Alert for February 7
The Omicron surge appears to be waning in the U.S., but a subvariant of Omicron seems to be surging in other countries where the Omicron surge faded.
PRESS RELEASES